Fresenius Medical Care to Cut Up to 5,000 Jobs on Covid Toll
(Bloomberg) -- Fresenius Medical Care AG plans to eliminate as many as 5,000 full-time positions as patient deaths from Covid-19 reduce the German kidney dialysis company's revenue prospects.
The company will spend 450 million euros ($522 million) to 500 million euros to fund the restructuring of its operations into two segments -- care enablement and care delivery, according to a statement Tuesday. The measures aim to save 500 million euros a year by the end of 2025.
Beyond the lost revenue from patient deaths, the company is also facing increased costs from safety measures and grappling with inflation. Dialysis recipients are at heightened risk of severe Covid. Throughout the pandemic more than 18,000 Fresenius Medical Care patients have died than would be expected from historical trends.
The company now expects revenue and profit at the lower end of its guidance range this year. While the company had forecast fatality rates to return to pre-pandemic levels by this summer, the delta wave in fact caused 2,700 more patient deaths in the third quarter than projected.
The “pandemic is an unprecedented situation for all of us and still costs many lives day by day,” Chief Executive Officer Rice Powell said in a statement.
The stock rose as much as 4.3% in Frankfurt.
The company previously guided for revenue to grow at a low- to mid-single digit percentage rate and net income to decline at a high-teens to mid-twenties percentage rate.
Operating income slid to 505 million euros in the third quarter. The company expects the steps to deliver net savings from 2023.
Separately, parent company Fresenius SE raised its full-year sales forecast and said it now expects 2021 earnings around the top end of its guided range.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.